FT596 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

**FT596 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone** is an investigational combination regimen designed for the treatment of relapsed or refractory B-cell lymphomas. FT596 is an allogeneic, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy that is genetically engineered with three antitumor modalities: a CD19-specific CAR, a high-affinity, non-cleavable CD16 Fc receptor for antibody-dependent cellular cytotoxicity (ADCC) in combination with anti-CD20 antibodies (e.g., rituximab), and an interleukin-15/IL-15 receptor fusion for improved NK cell persistence and function. Rituximab is an anti-CD20 monoclonal antibody. Cyclophosphamide, doxorubicin, and vincristine are cytotoxic small molecule chemotherapies, while prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects. The combination leverages the cytotoxicity of chemotherapy and immunotherapy (NK cell therapy and monoclonal antibody), providing a multi-antigen targeting and persistent immune response. This approach is primarily being investigated in patients with relapsed or refractory B-cell lymphoma, including both indolent and aggressive histologies[1][3][5][7][9].